{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:38:25Z","timestamp":1792852705929,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40256-025-00787-0","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T12:24:42Z","timestamp":1769343882000},"page":"305-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting Factor XI for Safer Anticoagulation: Emerging Data and Future Directions"],"prefix":"10.1007","volume":"26","author":[{"given":"Francesca","family":"Campanella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Giubilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Alagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Mario","family":"Giamundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sabouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-6382","authenticated-orcid":false,"given":"Giuseppe","family":"And\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"issue":"10","key":"787_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/17425255.2018.1530213","volume":"14","author":"Y Ingrasciotta","year":"2018","unstructured":"Ingrasciotta Y, Crisafulli S, Pizzimenti V, Marciano I, Mancuso A, Ando G, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018;14(10):1057\u201369. https:\/\/doi.org\/10.1080\/17425255.2018.1530213.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl B","key":"787_CR2","doi-asserted-by":"publisher","first-page":"B65","DOI":"10.1093\/eurheartjsupp\/suad070","volume":"25","author":"F Muscente","year":"2023","unstructured":"Muscente F, De Caterina R. The new in anticoagulation: factor XI inhibitors. Eur Heart J Suppl. 2023;25(Suppl B):B65\u20138. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad070.","journal-title":"Eur Heart J Suppl"},{"issue":"6","key":"787_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1055\/s-0033-1353420","volume":"39","author":"S Duga","year":"2013","unstructured":"Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013;39(6):621\u201331. https:\/\/doi.org\/10.1055\/s-0033-1353420.","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"787_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1056\/NEJMe2414209","volume":"392","author":"DJ Angiolillo","year":"2025","unstructured":"Angiolillo DJ, Capodanno D. Uncoupling thrombosis and hemostasis by inhibiting factor XI. N Engl J Med. 2025;392(4):400\u20133. https:\/\/doi.org\/10.1056\/NEJMe2414209.","journal-title":"N Engl J Med"},{"issue":"10","key":"787_CR5","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.3324\/haematol.2023.283682","volume":"109","author":"O Cohen","year":"2024","unstructured":"Cohen O, Santagata D, Ageno W. Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings. Haematologica. 2024;109(10):3110\u201324. https:\/\/doi.org\/10.3324\/haematol.2023.283682.","journal-title":"Haematologica"},{"issue":"8","key":"787_CR6","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s11239-024-02972-5","volume":"57","author":"AE Ali","year":"2024","unstructured":"Ali AE, Becker RC. Factor XI: structure, function and therapeutic inhibition. J Thromb Thrombolysis. 2024;57(8):1315\u201328. https:\/\/doi.org\/10.1007\/s11239-024-02972-5.","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"787_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","volume":"147","author":"A Greco","year":"2023","unstructured":"Greco A, Laudani C, Spagnolo M, Agnello F, Faro DC, Finocchiaro S, et al. Pharmacology and clinical development of factor XI inhibitors. Circulation. 2023;147(11):897\u2013913. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062353.","journal-title":"Circulation"},{"issue":"6","key":"787_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","volume":"151","author":"F Gragnano","year":"2025","unstructured":"Gragnano F, van Klaveren D, Heg D, Raber L, Krucoff MW, Raposeiras-Roubin S, et al. Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention. Circulation. 2025;151(6):343\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072009.","journal-title":"Circulation"},{"issue":"6","key":"787_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jacbts.2024.12.005","volume":"10","author":"J Liang","year":"2025","unstructured":"Liang J, Nilsson S, Wikstrom J, Cao H, Zheng S, Xu Q, et al. Inhibition of factor XI using RBD4059: a novel GalNAc-siRNA with potent and durable antithrombotic effects. JACC Basic Transl Sci. 2025;10(6):786\u201397. https:\/\/doi.org\/10.1016\/j.jacbts.2024.12.005.","journal-title":"JACC Basic Transl Sci"},{"issue":"8","key":"787_CR10","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s11239-024-02985-0","volume":"57","author":"AE Ali","year":"2024","unstructured":"Ali AE, Becker RC. The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease. J Thromb Thrombolysis. 2024;57(8):1283\u201396. https:\/\/doi.org\/10.1007\/s11239-024-02985-0.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"787_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02055-x","volume":"7","author":"DA Donkor","year":"2017","unstructured":"Donkor DA, Bhakta V, Eltringham-Smith LJ, Stafford AR, Weitz JI, Sheffield WP. Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Sci Rep. 2017;7(1):2102. https:\/\/doi.org\/10.1038\/s41598-017-02055-x.","journal-title":"Sci Rep"},{"key":"787_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.thromres.2017.06.015","volume":"156","author":"RS Woodruff","year":"2017","unstructured":"Woodruff RS, Ivanov I, Verhamme IM, Sun MF, Gailani D, Sullenger BA. Generation and characterization of aptamers targeting factor XIa. Thromb Res. 2017;156:134\u201341. https:\/\/doi.org\/10.1016\/j.thromres.2017.06.015.","journal-title":"Thromb Res"},{"key":"787_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22083897","author":"M Liu","year":"2021","unstructured":"Liu M, Zaman K, Fortenberry YM. Overview of the therapeutic potential of aptamers targeting coagulation factors. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22083897.","journal-title":"Int J Mol Sci"},{"issue":"10333","key":"787_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399(10333):1383\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1.","journal-title":"Lancet"},{"issue":"10357","key":"787_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022;400(10357):997\u20131007. https:\/\/doi.org\/10.1016\/S0140-6736(22)01588-4.","journal-title":"Lancet"},{"issue":"16","key":"787_CR16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","volume":"146","author":"SV Rao","year":"2022","unstructured":"Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022;146(16):1196\u2013206. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061612.","journal-title":"Circulation"},{"issue":"1","key":"787_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2407105","volume":"392","author":"JP Piccini","year":"2025","unstructured":"Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, et al. Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med. 2025;392(1):23\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2407105.","journal-title":"N Engl J Med"},{"issue":"6","key":"787_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamacardio.2025.0277","volume":"10","author":"JH Alexander","year":"2025","unstructured":"Alexander JH, Lydon EJ, Piccini JP, Viethen T, Oldgren J, Goodman SG, et al. Asundexian or apixaban in patients with atrial fibrillation according to prior oral anticoagulant use: a subgroup analysis of the OCEANIC-AF randomized clinical trial. JAMA Cardiol. 2025;10(6):555\u201363. https:\/\/doi.org\/10.1001\/jamacardio.2025.0277.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"787_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/cts.13148","volume":"15","author":"V Perera","year":"2022","unstructured":"Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, et al. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022;15(2):330\u201342. https:\/\/doi.org\/10.1111\/cts.13148.","journal-title":"Clin Transl Sci"},{"issue":"23","key":"787_CR20","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2113194.","journal-title":"N Engl J Med"},{"issue":"1","key":"787_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","volume":"23","author":"M Sharma","year":"2024","unstructured":"Sharma M, Molina CA, Toyoda K, Bereczki D, Bangdiwala SI, Kasner SE, et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2024;23(1):46\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(23)00403-9.","journal-title":"Lancet Neurol"},{"key":"787_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","volume":"277","author":"SS Jain","year":"2024","unstructured":"Jain SS, Mahaffey KW, Pieper KS, Shimizu W, Potpara T, Ruff CT, et al. Milvexian vs apixaban for stroke prevention in atrial fibrillation: the LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024;277:145\u201358. https:\/\/doi.org\/10.1016\/j.ahj.2024.08.011.","journal-title":"Am Heart J"},{"key":"787_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ahj.2025.02.011","volume":"285","author":"CM Gibson","year":"2025","unstructured":"Gibson CM, Bahit MC, Mehran R, Mehta SR, Lamee RA, Goto S, et al. Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: rationale and design of the phase 3 (Librexia ACS). Am Heart J. 2025;285:21\u20138. https:\/\/doi.org\/10.1016\/j.ahj.2025.02.011.","journal-title":"Am Heart J"},{"issue":"7","key":"787_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Buller HR, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385(7):609\u201317. https:\/\/doi.org\/10.1056\/NEJMoa2105872.","journal-title":"N Engl J Med"},{"issue":"4","key":"787_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1056\/NEJMoa2406674","volume":"392","author":"CT Ruff","year":"2025","unstructured":"Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, et al. Abelacimab versus rivaroxaban in patients with atrial fibrillation. N Engl J Med. 2025;392(4):361\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2406674.","journal-title":"N Engl J Med"},{"issue":"2","key":"787_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323(2):130\u20139. https:\/\/doi.org\/10.1001\/jama.2019.20687.","journal-title":"JAMA"},{"issue":"2","key":"787_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","volume":"30","author":"JI Weitz","year":"2024","unstructured":"Weitz JI, Tanko LB, Floege J, Fox KAA, Bhatt DL, Thadhani R, et al. Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial. Nat Med. 2024;30(2):435\u201342. https:\/\/doi.org\/10.1038\/s41591-023-02794-7.","journal-title":"Nat Med"},{"issue":"22","key":"787_CR28","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021011725","volume":"138","author":"CU Lorentz","year":"2021","unstructured":"Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138(22):2173\u201384. https:\/\/doi.org\/10.1182\/blood.2021011725.","journal-title":"Blood"},{"issue":"3","key":"787_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR Buller","year":"2015","unstructured":"Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1405760.","journal-title":"N Engl J Med"},{"issue":"2","key":"787_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","volume":"7","author":"M Walsh","year":"2022","unstructured":"Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Yu RZ, et al. Phase 2 study of the factor XI antisense inhibitor IONIS-FXI(Rx) in patients with ESRD. Kidney Int Rep. 2022;7(2):200\u20139. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.011.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"787_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","volume":"106","author":"WC Winkelmayer","year":"2024","unstructured":"Winkelmayer WC, Lensing AWA, Thadhani RI, Mahaffey KW, Walsh M, Pap AF, et al. A phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney Int. 2024;106(1):145\u201353. https:\/\/doi.org\/10.1016\/j.kint.2024.02.024.","journal-title":"Kidney Int"},{"issue":"Supplement_1","key":"787_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.3327","volume":"45","author":"A Gabrielsen","year":"2024","unstructured":"Gabrielsen A, Feng Z, Fu J, Ueckert S, Egnell L, Wikstrom J, et al. First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects. Eur Heart J. 2024;45(Supplement_1):ehae666.3327. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.3327.","journal-title":"Eur Heart J"},{"key":"787_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ijcard.2016.11.303","volume":"231","author":"G Ando","year":"2017","unstructured":"Ando G, Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis. Int J Cardiol. 2017;231:162\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.303.","journal-title":"Int J Cardiol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00787-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:36:44Z","timestamp":1776857804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00787-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00787-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesca Campanella, Francesco Barreca, Simona Giubilato, Giulia Alagna, Giovanni Taverna, Domenico Mario Giamundo, Ahmed Ibrahim, Pierre Sabouret, Francesco Amico, and Giuseppe And\u00f2 declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Francesca Campanella, Francesco Barreca, and Giuseppe And\u00f2 conceived and designed the study and wrote the first draft of the manuscript. Simona Giubilato, Giulia Alagna, Giovanni Taverna, Ahmed Ibrahim, Pierre Sabouret, and Domenico Mario Giamundo contributed to content development. All authors contributed to the revision of the manuscript and approved the final version. Francesco Amico and Giuseppe And\u00f2 critically revised the manuscript and acted as institutional supervisors, taking responsibility for the integrity of the work as a whole.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Data sharing not applicable to this article as no datasets were generated for it.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}